Table 3.

GEP testing and Serious Chemotherapy-associated Adverse Events.

		Clinical Recurrence Risk
	All Patients	Low	Moderate	High
n	534	60	204	253
Occurrence of adverse event	56 (10.5%)	2 (3.3%)	21 (10.3%)	30 (11.9%)
Received GEP test	138 (25.8%)	15 (25.0%)	106 (52.0%)	14 (5.5%)
	Odds Ratio for Serious Chemotherapy-associated Adverse Events (95% confidence interval)
Received GEP test
Unadjusted	0.59 (0.24 – 1.22)	-	0.53 (0.21 – 1.35)	0.56 (0.07 – 4.42)
Adjusted for propensity to receive a GEP test	0.54 (0.24 – 1.22)	-	0.55 (0.21 – 1.43)	0.56 (0.06 – 4.34)

NOTES: Reference in adjusted analyses is women who did not receive a GEP test. Each woman’s propensity to receive a GEP test was estimated as a function of her age at diagnosis, comorbidity score, year of diagnosis, tumor size, grade, nodal status, estrogen and progesterone receptor status, and HER2 receptor status, and was categorized in tertiles in adjusted model. Models not run for low clinical risk group because of limited sample size.